Where does Envizion Medical Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Envizion Medical Ltd. ranks #16,777 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Envizion Medical Ltd. hold?

Envizion Medical Ltd. holds 17 US utility patents granted between 2019 and 2023, spanning 4 technology areas.

What is Envizion Medical Ltd.'s Innovation Score?

Envizion Medical Ltd. has an Innovation Score of 31.5 out of 100 (38th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Envizion Medical Ltd.'s patent grant rate increasing or decreasing?

Envizion Medical Ltd.'s recent grant velocity is +650% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Envizion Medical Ltd.'s patents?

Envizion Medical Ltd.'s patents average 14.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Envizion Medical Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Envizion Medical Ltd.

Q: What technology areas does Envizion Medical Ltd. focus on?

Envizion Medical Ltd.'s top technology area is A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle) with 15 patents, ranking #58 of 903 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 17 granted patents across 4 technology areas, recorded in grant years 2019–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Envizion ranks #16,777 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 4 technology areas.

#16,777
of 49,997 US assignees by volume: 38th percentile
by Innovation Score (31.5/100): 14.2
avg claims per patent: +650%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16777 · Foreign Corporation #16,777 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 17 grants
MID-PACK #16,777/49,997
PHOTO-FINISH Emag Holding
CPC-NARROW A61J · 4 areas
INNOV-THIN 31.5/100
CLAIMS-RICH 14.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +650% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Emag Holding GMBH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Envizion’s 31.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.0 pts (32%) Velocity 5.9 pts (19%) Breadth 7.1 pts (23%) Claim depth 8.5 pts (27%)

Qualcomm Incorporated · highest

85
Envizion Medical · this assignee

32
3D Lighting… · lowest

7

What this shows Envizion's Innovation Score is 31.5/100 (38th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Envizion?

Each dot is one of Envizion’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Envizion’s own 14.2 claims/patent is at or below the 15.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Envizion vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Envizion's grants concentrate

Envizion Medical Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 88.2% of grants classified under A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ). Peak complete grant year is 2023 (5 grants) versus a trough of 2 in 2019. By volume, Envizion sits between Emag Holding GMBH and EVR Motors Ltd.

Envizion's three-year grant acceleration

Envizion Medical Ltd. shows 8 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Emag Holding

17
Emoji ID

17
Enercorp Engineer…

17
Energy Focus

17
Enzymotec

17
Erdos Miller

17
Etex Services

17
EVR Motors

17
Envizion Medical ◀

17

What this shows Envizion holds 17 patents at rank #16,764, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Envizion

By rank, the assignees closest to #16,764 in granted patent volume.

Leaders in A61J (Containers Specially Adapted FOR Medical OR Pharmaceutica…)

Other assignees with the most granted patents in Envizion's primary technology class.

Envizion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 38th percentile higher than 38% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Envizion Medical Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	2	11.8%
2020	4	23.5%
2021	3	17.6%
2022	3	17.6%
2023	5	29.4%

Which technologies does Envizion Medical Ltd. patent most?

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 15

A61B - DIAGNOSIS; SURGERY; Identification 9

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 8

A61H - Physical Therapy Apparatus, e.g. Devices FOR Locating OR Stimulating Reflex Points IN THE BODY; Artificial RESPIRATION; MASSAGE; Bathing Devices FOR Special Therapeutic OR Hygienic Purposes OR Specific Parts OF THE Body 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Envizion Medical Ltd.'s patent record in context - here's where to go next.

Envizion Medical Ltd.'s lead technology class is A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ), 88.2% of its portfolio - see every assignee active in that class. Explore A61J
Ranked #16,777 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Envizion Medical Ltd. against Emag Holding GMBH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.